We seek to determine the genetic mutations that drive myeloid malignancies, the clinical consequences of specific mutations, and the biological basis of malignant transformation.
We systematically dissect the the genetics of pre-malignant states in blood cancers and examine the effects of these pre-malignant states on the development of both cancer and non-malignant diseases.
We explore the development of novel therapeutics that modulate ubiquitin ligase activity to induce targeted protein degradation.
